Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01198769
Recruitment Status : Completed
First Posted : September 10, 2010
Results First Posted : April 17, 2012
Last Update Posted : October 20, 2016
Information provided by (Responsible Party):

September 9, 2010
September 10, 2010
March 22, 2012
April 17, 2012
October 20, 2016
November 2010
April 2011   (Final data collection date for primary outcome measure)
Number of Seroconverted Subjects for Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody. [ Time Frame: 2 months post-Dose 2 (at study Month 4) ]
Seroconversion is defined as the appearance of IgA antibody concentration equal to or above (≥) 20 Units per millilitre (U/mL) in the serum of subjects who were seronegative before vaccination. A seronegative subject is a subject with anti-rotavirus IgA antibody concentration below (<) 20 U/mL.
Immunogenicity to study vaccine antigen [ Time Frame: Two months after the second vaccine dose ]
Complete list of historical versions of study NCT01198769 on Archive Site
  • Serum Anti-rotavirus IgA Antibody Concentrations. [ Time Frame: 2 months post-Dose 2 (at study Month 4) ]
    Concentrations were expressed as geometric mean antibody concentration in units per millilitre (U/mL), calculated on all subjects.
  • Number of Subjects Reporting Solicited General Symptoms. [ Time Frame: During the 8-day (Days 0-7) post-vaccination period ]
    Solicited general symptoms assessed were cough, diarrhoea, irritability, loss of appetite, temperature (any temperature was defined as a tympanic on rectal setting temperature ≥ 38.0 degrees Celsius) and vomiting.
  • Number of Subjects With Rotavirus (RV) Present in the Gastroenteritis (GE) Stool Sample. [ Time Frame: From Day 0 (first vaccine dose) to study Month 4 (2 months post-Dose 2) ]

    RV was not identified in the one GE stool sample collected in the study. Two subjects reported GE episode between vaccination Dose 1 and before vaccination Dose 2. For one of them, GE stool sample was not collected and for the other subject no RV was identified in the GE stool sample.

    GE symptoms were defined as diarrhoea with or without vomiting. A GE stool sample was collected as soon as possible after the illness began by the parent/guardian of the subject. Presence of RV antigen was detected by Enzyme-linked immunosorbent assay (ELISA).

  • Number of Subjects Reporting Unsolicited Adverse Events (AEs). [ Time Frame: Within the 31-day (Days 0-30) follow-up period after vaccination ]
    An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
  • Number of Subjects Reporting Serious Adverse Events (SAEs). [ Time Frame: During the entire study period (from Dose 1 at Day 0 up to Month 4) ]
    SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
  • Immunogenicity to study vaccine antigen [ Time Frame: Two months after the second vaccine dose ]
  • Occurrence of each type of solicited symptom [ Time Frame: During the 8-day (Day 0 - Day 7) follow-up period after each vaccine dose. ]
  • Occurrence of unsolicited adverse event [ Time Frame: Within the 31-day (Day 0 - Day 30) follow-up period after any vaccine dose ]
  • Occurrence of serious adverse events [ Time Frame: Throughout the study period (Day 0 up to Month 4) ]
  • Presence of rotavirus in gastroenteritis stool samples. [ Time Frame: From Dose 1 (Day 0) up to study end (Month 4). ]
Not Provided
Not Provided
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
Immunogenicity, Reactogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
The purpose of this study is to assess immunogenicity and safety of Rotarix TM when administered in healthy Taiwanese infants (aged 6 to 12 weeks at the time of first vaccination) who received Hepatitis B immunoglobulin after birth.
Not Provided
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Infections, Rotavirus
Biological: Rotarix TM
Oral, 2 doses
Experimental: Rotarix Group
subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
Intervention: Biological: Rotarix TM
Lu CY, Chang LY, Shao PL, Suryakiran PV, Han HH, Huang LM. Immunogenicity, reactogenicity, and safety of a human rotavirus vaccine, Rotarix, in Taiwanese infants who received a dose of hepatitis B immunoglobulin after birth. J Formos Med Assoc. 2013 Sep;112(9):574-7. doi: 10.1016/j.jfma.2012.11.016. Epub 2013 Jan 3.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
April 2011
April 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.
  • A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
  • Written informed consent obtained from the parent(s)/Legally Acceptable Representative(s) of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Infants who have received a previous dose of hepatitis B immunoglobulin after birth.

Exclusion Criteria:

  • Child in care.
  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of immunosuppressants or other immune-modifying drugs with the exception of Hepatitis B immunoglobulin since birth. Child is unlikely to remain in the study area for the duration of the study.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous vaccination against rotavirus.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • Family history of congenital or hereditary immunodeficiency.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • Acute disease and/or fever at the time of enrolment.
  • Administration of immunoglobulins (with the exception of HBIG) and/or any blood products since birth or planned administration during the study period.
  • Gastroenteritis within 7 days preceding the study vaccine administration.
  • Previous confirmed occurrence of Rotavirus gastroenteritis.
Sexes Eligible for Study: All
6 Weeks to 12 Weeks   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Plan to Share IPD: Yes
Plan Description: Patient-level data for this study will be made available through following the timelines and process described on this site.
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP